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Abstract
As the aging of society, metabolic disorders have become a major concern and a major 
cause for cardio- and neurovascular diseases such as atherosclerosis, stroke, and even 
cognitive decline. This chapter shows the progressive plaque formation mechanisms and 
regression under autophagic flow in both experimental and clinical side. Atherosclerotic 
plaque formation is not irrevocable. Clinical and experimental reports accept that ath-
erosclerosis can regress after statin treatment. This chapter focuses on autophagic roles 
in atherosclerotic plaque formation, progression, and regression. Another focus is on 
the relationship between atherosclerosis and an increased risk of cognitive decline and 
further conversion from mild cognitive impairment (MCI) to dementia. There has been 
broad and strong support on the relationship between atherosclerotic severity and cog-
nitive function. Ultrasound findings such as intima-media thickness (IMT) and plaque 
numbers could potentially be useful in identifying individuals with a higher risk of 
progression from cognitive decline according to morphological criteria. This also sug-
gests the possibility as a predictive indicator of MCI and dementia by considering the 
presence of atherosclerotic changes. Focusing on therapeutics, this chapter provides 
mechanisms for regressing atherosclerotic plaques. Autophagy suggests therapeutic 
possibilities for atherosclerosis and it consequently paves the way for preventing cogni-
tive impairment.
Keywords: atherosclerosis, autophagy, mild cognitive impairment, dementia, 
neurovascular
1. Pathogenesis of atherosclerosis
Cardio and cerebrovascular disease are leading causes of mortality worldwide. Mainly, they 
are caused by atherosclerosis, which is a chronic inflammatory disease of blood  vessels. 
Cardiovascular events in the arterial wall result from the interactions between lipoproteins 
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and macrophages [1]. Accumulated lipoproteins bound to infiltrated macrophages to form 
a fibrous cap composed mostly of collagen in vascular smooth muscle cells, and this devel-
ops into an atherosclerotic plaque [2]. The developed plaque can cause stenosis, which can 
lead to ischemic conditions in surrounding tissues. When a plaque ruptures, in the worst-
case scenario, thrombogenic materials are exposed, platelets are aggregated, and they 
form a thrombus. The detached thrombus becomes an embolus capable of blocking blood 
flow. Thus, atherothrombosis has the capability to cause ischemic stroke and myocardial 
infarction.
Lipoproteins transport cholesterol through the blood. Low-density lipoprotein (LDL) 
consists of esterified cholesterol and triglycerides that contain phospholipids, free cho-
lesterol, and apolipoprotein B100 (ApoB100) [3]. Cellular LDL uptake is well-regulated. 
Their feedback mechanisms systemically limit excessive uptake and lipid overload in cells 
[4]. In contrast, oxidized LDL (oxLDL) mostly bypasses the feedback system, and results 
in intracellular lipid accumulation as foam cells present in atherosclerotic plaques [5]. 
Generally, the scavenger receptor-mediated uptake system misses the modified lipopro-
teins such as oxidized forms of LDL. During oxidation, physico-chemical properties such 
as lipid charge, size, and content are changed. Because oxidation modifies the LDL par-
ticles, oxLDL particles have already undergone physico-chemical changes. The oxLDL is 
technically different from natural LDL. The components of oxLDL can activate endothelial 
cells, and also induce the expression of adhesion molecules (E-selectin and VCAM-1) on 
the endothelial surface of the artery [2]. With endothelial activation by these oxidized lip-
ids, oxLDL help macrophages to infiltrate into tissues and to produce chemokines as well 
as adhesion molecules [6].
The role of macrophages is critical in the development of atherosclerosis. Macrophages infil-
trate to the arterial intima in response to oxLDL in the vessel. Macrophages engulf various lip-
ids containing oxLDL and show a changed phenotype in comparison to lipid-laden foam cells. 
Spontaneously, they progress to a pro-inflammatory state. This is an early event in forming 
atherosclerotic lesion plaques. Macrophages secrete pro-inflammatory cytokines and recruit 
additional macrophages into the artery, and continuously increase atherosclerotic plaque size 
and complexity [7]. The early events of atherosclerosis induce additional immune cell infiltra-
tion and a progressive dysfunction to initiate a cell death pathway [5]. When atherosclerotic 
lesions develop, apoptotic as well as necrotic cell death occur. Cell debris and cholesterol form 
a necrotic core in the lesion covered by a fibrous cap of variable thickness [8]. Atherosclerosis 
forms under chronic exposure to cellular stressors, which promotes accumulated lipid degrad-
ing cascades and consequently dysfunction. It has been revealed that macrophage autophagy 
is linked to lipid metabolism [7]. In atherosclerotic plaques, there is intracellular accumula-
tion of LDL as well as damaged tissue and misfolded/aggregated proteins. Biologically, these 
extra-accumulating materials are dealt via autophagy. Through the use of adapter proteins, 
the cells undergo autophagy. The process involves selective events rather than random bulk 
cleavage [9]. The selective autophagy can be described as: mitophagy, handling mitochondria; 
pexophagy, charging on peroxisomes; lipophagy, dealing with lipids; aggrephagy, taking care 
of aggregated proteins; and xenophagy, treating microorganisms. Among them, lipophagy is 
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the initiating event of autophagy by mediating a cholesterol efflux [10]. It has slowly become 
clear that an atherosclerotic macrophage can induce and degrade cargo lipids by selective 
autophagy. In the case of the chaperone protein p62/SQSTM1 in chaperone-mediated autoph-
agy (CMA), p62/SQSTM1 can hold and transfer poly-ubiquitinated cargo to autophagosomes 
for degradation. This machinery performs degrading events through the ubiquitin-binding 
domain (UBD) and the LC3-interacting region (LIR) [11]. The dysregulation of this autophagic 
pathway results from the markedly elevated p62/SQSTM1 protein levels in macrophages of 
the atherosclerotic plaque [12].
It is apparent that inflammatory factors and inflammatory reactions play critical roles in ath-
erothrombotic disease. However, this chapter will focus on the autophagic pathway and dys-
regulated autophagy among contributors (members) to atherothrombosis.
2. Autophagic regulation and dysfunction in atherosclerosis
Autophagy literally means “to eat oneself” and originated in Greek. It is an evolutionary 
conserved mechanism, that is, a catabolic process to degrade cytoplasmic contents such as cel-
lular proteins and organelles through lysosomes for recycling and use in downstream metab-
olism [13]. Biomolecules degrade and generate free fatty acids, amino acids, and nucleotides, 
which can be reused by the cell to maintain energy production and protein synthesis [13]. 
Degradation of intracellular molecules occurs through two distinct systems: the ubiquitin-
proteasome system and the lysosome-autophagy system [14, 15]. In mammals, autophagy 
is the major pathway used to degrade abnormal products besides the ubiquitin-proteasome 
system. Autophagy is primarily used for the removal of damaged organelles, abnormal pro-
teins, and protein aggregates [16], and this housekeeping function is particularly essential in 
the heart and brain. When autophagy-specific genes are lacking, a severe cardiomyopathy or 
neurodegeneration occurs [17].
There are several types of autophagy according to the method of delivery of the cargo 
to lysosomes: macroautophagy, microautophagy, and chaperone-mediated autophagy 
(CMA) [18]. Macroautophagy is the predominant mechanism among these three types. 
Macroautophagy starts with the formation of double-membrane vesicles, autophago-
somes. Autophagosomes fuse with lysosomes and finally progress to autolysosomes. 
Physiological stress conditions such as starvation upregulates autophagy. Identified genes 
and molecules involved include around 30 genes and they are called autophagy-related 
genes (ATGs) required for autophagic pathways [19]. Among them, ATG5 and ATG12 are 
involved in the first step, controlling autophagy with two ubiquitylation-like reactions. 
ATG12 links to ATG5 requiring ATG7 (serves as an ubiquitin-activating enzyme, E1) and 
ATGT10 (serves as an ubiquitin-activating enzyme, E2). Then, the ATG5-ATG12 complex 
is involved in autophagosome formation. Autophagosomes randomly formed in the cyto-
plasm are trafficked along microtubules to lysosomes in a way that is dynein-dependent. 
Autophagosomes, then, are fused with lysosomes. The SNARE proteins of yeast are thought 
to be involved in this fusion [20, 21].
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Microautophagy raises the possibility of direct cytoplasmic engulfment by the lysosome 
in mammals or the vacuole in plant and fungi [22]. In macroautophagy, a double- or 
multi-membrane-surrounded autophagosome forms, which fuse with lysosomes in a non-
specific way for degradation [22]. In contrast to macroautophagy, in microautophagy, the 
lysosomal/vacuolar membrane is randomly engulfed and differentiates into the autopha-
gic tube enclosing the cytosolic portion [23]. Microautophagy starts with making mem-
brane knobs into the surface of the lysosome, and constructs small smooth areas that are 
able to degrade. The invaginations move laterally and also can shrink, which are speci-
fied into particular tubular shape “autophagic tubes” [23]. This characteristic is unique 
and gives them an autophagic function. After that, a dramatic decrease occurs along with 
the autophagic tube intramembranous proteins toward the top of the tube. Collectively, 
microautophagy performs degradation of cargo lipids and proteins in the following order: 
vesicle formation, vesicle expansion, vesicle scission, and eventual vesicle degradation and 
recycling [22].
Another case of autophagy is chaperone-mediated autophagy (CMA). Cargo recognition in 
macroautophagy has a non-selective process, because soluble cytosolic proteins cannot be 
selected as single protein molecules and are targeted for degradation through this pathway 
[24]. CMA targets only single proteins. In CMA, proteins are identified one by one, and the 
identified proteins are degraded by using a cytosolic chaperone system that delivers them to 
the surface of the lysosomes [25]. Selectivity in CMA uses a pentapeptide amino acid sequence 
motif in the substrate proteins. When the substrate proteins are recognized by a cytosolic 
chaperone, it results in targeting substrates to lysosomes [26]. CMA proceeds in sequential 
multi-steps: (i) recognition of substrate proteins; (ii) binding and unfolding of substrates; 
(iii) translocation of substrates inside the lysosomes; and (iv) degradation of substrates in the 
lysosomal lumen through its cellular functions [27].
CMA-targeting motifs are generated through posttranslational modifications with KFERQ 
on the targets. This pentapeptide was first reported to be critical in the degradation of RNase 
A [28], and it is shared by all identified substrate proteins to date [24]. The proteins carrying 
the KFERQ motif are targeted by a constitutive chaperone, the heat shock-cognate protein 
of 70 kDa (Hsc70). Hsc70 is the only chaperone to interact with the substrate via regulated 
ATP/ADP binding cycles [29]. The chaperone Hsc70 combines the proteins with a KFERQ 
motif, and binds with the cytosolic tail of the single-span membrane protein lysosome-asso-
ciated membrane protein type 2A (LAMP-2A19, LAMP-2A), which shuttles the chaperone 
complex and the targeted protein into the lysosomal lumen [29]. Hsc70 also interacts with 
protein aggregates, and has mediated their degradation by macroautophagy, which is called 
a chaperone-assisted selective autophagy (CASA) [30]. This reaction works the same way on 
a responsible disassembly of clathrin from coated vesicles, and is needed to fold the unfolded 
cytosolic proteins upon recognition of exposed hydrophobic regions [28]. Once the substrate 
is translocated into the lysosomal lumen, LAMP-2A is rapidly dissembled from the complex 
into monomers, which endows LAMP-2A to bind with other substrates again [27]. LAMP-2A 
is one of the three splice variants of the lamp2 gene [9], and is a single-span membrane protein. 
There is a very heavily glycosylated luminal region and a short (12-amino acid) C-terminus 
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tail in LAMP-2A. When they are exposed on the surface of the lysosomes, substrate proteins 
bind to them [25].
2.1. Autophagy in VSMC of atherosclerotic plaques
The general architecture and cellular composition of blood vessels have basic components in 
the wall of blood vessels: endothelial cells (EC), vascular smooth muscle cells (VSMC), and 
extracellular matrix (ECM), including elastin, collagen, and glycosoaminoglycans. Each ves-
sel is composed of the three concentric layers intima, media, and adventitia [31]. In normal 
mature blood vessels, VSMC predominantly exist in a contractile or differentiated pheno-
type that regulates blood flow and blood vessel diameter with vasodilation and vasocon-
striction. The contractile VSMCs are surrounded by their own basement membrane, some 
macrophages, and fibroblasts. When damaged, VSMC generates intimal vascular lesions. The 
VSMC layers of the nearest vessel lumen receive oxygen as well as nutrients by direct diffu-
sion from the vessel lumen.
VSMC in atherosclerosis consists of aberrantly proliferated VSMC to promote plaque forma-
tion. However, VSMC in advanced plaques is involved in preventing rupture of the fibrous 
cap [32]. The tensile strength of the protective cap relies on structural properties that are deter-
mined by the number of VSMCs and the collagen [33]. This is the reason why loss of VSMC 
leads to plaque destabilization and rupture. In advanced plaques, disintegrating VSMCs in 
the fibrous cap undergo programmed cell death, which is not apoptosis but autophagy. This 
has been shown in electron-microscopy imaging as formation of myelin figures [34], accu-
mulation of ubiquitinated inclusions in the cytosol [13], and severe vacuolization [34]. In this 
stage, macrophages actively induce SMC death [13].
VSMCs loading a lot of cholesterol activate multiple pro-inflammatory genes and are 
altered to form macrophage-like cells driven by lipid accumulation in the plaque, and are 
then induced to perform phagocytic activity [32]. In the fibrous cap of advanced human 
plaques, VSMCs die showing ubiquitinated inclusions indicating they are undergoing 
autophagic death [13, 19]. Actually, the fibrous cap is a thick layer of basal lamina. It may 
be easier to let these “caged” cells undergo autophagy. Also, it has been suggested in in 
vitro studies that caged cells can trigger autophagy in atherosclerotic plaques. It has been 
reported in human plaques that lipid-laden VSMCs increase the expression of death-
associated protein (DAP) kinase, a pro-apoptotic mediator, and regulate the formation of 
autophagic vesicles [35].
Generally, autophagy is well-recognized as a survival mechanism under starvation and not as a 
death pathway [36]. In atherosclerotic plaques, autophagy most likely plays a safeguarding role 
for plaque cells against oxidative stress, a hallmark of advanced atherosclerotic lesions. The suc-
cessful autophagy in the atherosclerotic plaque is anti-apoptotic and eventually contributes to 
cellular recovery. However, it becomes another story under acute or persistent oxidative stress. 
In this case, over-produced intracellular ROS can be harmful to the lysosomal membrane. When 
autophagy does not work in the oxidative stress response in atherosclerotic plaques, or when 
oxidative injury overwhelms the cellular defenses, cells might undergo apoptosis.
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2.2. Autophagy in macrophages of atherosclerotic plaques
Macrophages are immune cells having a strong phagocytic potential. They migrate into tis-
sues derived from the differentiation of monocyte precursors in blood [7]. They are primarily 
involved in the phagocytosis against extracellular pathogens. They are also responsible for 
treating cellular debris, antigen presentation, and activation of the adaptive immune system. 
Macrophages secrete either pro- or anti-inflammatory cytokines according to their activa-
tion state [8]. Monocytes are recruited to the vessel intima, and they are initiated by chemo-
kines secreted from endothelial cells, which are activated by excess lipoprotein accumulation 
[21]. These events show a profound effect on the reduction of atherosclerotic plaque burden 
through a lower number of circulating monocytes or to prevent their interactions with the 
endothelium via chemokine/chemokine receptor blockage [37].
In atherosclerotic plaques, macrophages contribute to cytokine production, the maintenance 
of vessel wall inflammation, and finally atherosclerotic progression [38]. Inflammatory signal-
ing is a general and major event in atherosclerosis. Several other pathways, besides inflam-
mation signals, are triggered by macrophages involved in wreaking havoc on the plaque [7]. 
They are over-expressed reactive oxygen intermediates containing myeloperoxidase-induced 
reactive nitrogen species. Under oxidative stress, secreted cathepsins and matrix metallopro-
teinases (MMPs) worsen the sub-endothelial environment. This toxic environment results in 
a vicious cycle of lipoprotein oxidation, enhanced lipoprotein uptake, and increased inflam-
matory signaling [7]. When the membrane cholesterol content of macrophages exceeds their 
handling capacity, a lipid droplet is formed. Cells with lipid droplets are defined as foam 
cells in the atherosclerotic lesion. A primary response to such lipid overload is the efflux of 
excess cholesterol out of macrophages with the help of high-density lipoproteins (HDLs). This 
process occurs in the cytoplasm where a family of cholesteryl ester hydrolases releases cho-
lesterol from macrophage lipid droplets. This is followed by ATP-binding cassette transporter 
ABCA1 (ABCA-1), known as the cholesterol efflux regulatory protein (CERP). Finally, exog-
enously derived cholesteryl esters are hydrolyzed in lysosomes [7]. After that, the free choles-
terols are distributed to different cellular membrane compartments. In addition to cholesterol, 
the focal lipid substrate and other lipid species may affect macrophage lysosomal function [7].
Under physiological states in contrast to pathological states, most cells turn on compensatory 
mechanisms for handling such insults. Autophagy is one of the responses to toxic intermedi-
ates found in the atherosclerotic plaque, and autophagic processes concomitantly increase in 
macrophages [14]. Lipophagy was first discovered in the liver where a specific mechanism 
handles lipids [39]. It has also been evaluated in foam cell macrophages. Autophagic uptake 
of lipid droplets is subsequently subjected to lysosomal acid lipase (LAL)-dependent degra-
dation of cholesteryl esters in lysosomes. This is also an alternative mechanism of generating 
free cholesterol for ABCA1-mediated efflux to HDL [14]. It can be concluded that autophagy 
deficiency in macrophages increases macrophages’ susceptibility to foam cell formation. It 
is undoubtedly true that macrophage autophagy has an essential role in the atherosclerotic 
process. In mice lacking Atg5, atherosclerotic plaques are enlarged and overloaded with lip-
ids, there is extensive pro-inflammation, and the atherosclerotic core is filled with apoptotic 
and necrotic cells [7]. Recently, autophagy has been implicated in regulating cholesterol 
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efflux, suppressing inflammasome activation, and improving apoptosis in atherosclerotic 
macrophages.
2.3. Autophagy in vascular endothelial cells
Endothelial cells are arranged in many layers in large blood vessels in which they form a 
tough wall as connective tissue. The endothelial cells in mature vessels send signals to the sur-
rounding connective tissue, and take on an important part in regulating the vessel’s function 
and structure [40]. For regulating roles, the endothelial cells mediate fluid filtration, hormone 
trafficking, neutrophil recruitment, and finally maintaining hemostasis [41]. Endothelial cell 
dysfunction (ECD) in the artery is the first detectable change of a forming atherosclerotic 
lesion [42]. The changes in the sub-endothelial area contain: the focal permeation and trap-
ping, and the physiological and chemical modification of circulating lipoprotein particles [43].
The term endothelial dysfunction has already entered the lexicon of modern cardiovascular 
medicine [40]. However, the concept has not been developed to our present understanding 
of the cellular and molecular mechanisms of atherosclerosis. Under atherogenesis, the earlier 
characterization of endothelial dysfunction was focused on whether anatomical integrity of 
the intima was intact. The simplest definition of endothelial dysfunction is a lack of nitro 
oxide (NO), which is involved in various disease states: atherosclerosis, diabetes mellitus, 
coronary artery disease, hypertension, and hypercholesterolemia [41]. Endothelium-derived 
NO can modulate leukocyte adhesion. Endothelium-derived NO prevents leukocyte recruit-
ment to the vascular wall via the anti-inflammatory effects of NO. Endothelium-derived NO 
suppresses the expression level of VCAM-1, ICAM-1, and E-selectin, which respond to pro-
inflammatory cytokines. The cellular adhesion molecules mediate activation of the transcrip-
tion factor NF-κB, and NF-κB inhibited by endothelial NO prevents endothelial cell activation 
[44]. It has been found that inhibition of basal eNOS activity rapidly induces VCAM-1 and 
also increases monocyte adhesion [45]. This linkage could induce or enhance endothelial cell 
activation. The mediators of endothelial dysfunction such as hypercholesterolemia or oxi-
dative stress can lead to increasing vasoconstriction, smooth muscle proliferation, platelet 
aggregation, leukocyte adhesion, LDL oxidation, and MMP activation. In the vessel wall 
when there is turbulent flow, endothelial cell activation and atherosclerosis may occur more 
readily because there is less endothelium-derived NO. With support, atherosclerotic lesions 
develop more frequently at vascular branching sites when exposed to turbulent flow rather 
than laminar flow. In animal studies, eNOS deleted mice develop increased atherosclerosis 
and vascular inflammation [46].
In contrast to endothelial dysfunction, endothelial cell activation is defined by the endothelial 
cell surface adhesion molecules, such as VCAM-1, ICAM-1, and endothelial leukocyte adhe-
sion molecule (E-selectin) [41]. Endothelial cell activation is typically induced by pro-inflam-
matory cytokines, such as TNF-α and IL-6. When endothelial cells are activated, they facilitate 
the recruitment and attachment of circulating leukocytes to the vessel wall. Progressive struc-
tural remodeling of developing lesions starts with the formation of a fibrous cap. The lateral 
edges of these complicated atherosclerotic plaques contain a rich population of inflammatory 
cells such as activated macrophages, T-cells, natural killer T-cells (NK T-cell), and dendritic 
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cells. These inflammatory cells further modulate the endothelial cells into a pro-inflammatory 
phenotype, and have the endothelial cells work on structural instability of the plaque by mod-
ifying the proteolytic activity of extracellular matrix components [47].
Because of the above-mentioned characteristics, exogenous NO has been implicated as a ther-
apeutic target. NO has benefits in vascular inflammatory diseases, and some researchers have 
tried to ameliorate atherosclerosis and other vascular diseases with NO donor therapy [41]. 
The therapeutic use of NO therapy has been reported to ameliorate atherosclerosis [48]. It is 
an important aspect of therapy whether atherogenesis initiates the formation of endothelial 
dysfunction or activation. Although it is unclear how endothelial cells recruit inflammatory 
cells, it is clear that inflammatory cytokines secretion of endothelial cells is tightly linked to 
eNOS expression. This relationship gives us hints for therapy. Also, vascular endothelium-
derived NO has a protective role extending to endothelial-leukocyte interactions, leukocyte 
trafficking to hinder platelet activation, and smooth muscle contraction and proliferation. 
Statins (HMG-CoA reductase inhibitors) restore endothelial function, and protect vessels by 
boosting endothelium-derived NO. Endostatin has been reported to induce autophagic cell 
death in human endothelial cells (EA.hy926) [49]. When human endothelial cells are exposed 
to oxLDL, autophagy in the cells is increased to deal with plaque components. It is accepted 
that endostatin induces damaged endothelial cells by overloaded lipid through autophagic 
cell death pathways [50].
3. Atherothrombosis stabilization and regression mechanism
Atherosclerotic plaque lesions are generally asymptomatic for years with slowly evolving 
in restricting blood flow around lesion [51]. The transition between stable and unstable is 
decided by the development of a large necrotic core resulting from cell death within the 
plaque and failure to clearing dead cells. Macrophages are key players in the transition from 
stable to unstable lesions [52].
Primarily, autophagy is recognized as a survival mechanism and not as one of the cell 
death pathways. This renders the role of autophagy in atherosclerosis to be equivocal [53]. 
Successful autophagy generally contributes to cellular survival by acting anti-apoptosis and 
cellular recovery by supplying biomaterials. Autophagy serves as safeguards for atheroscle-
rotic plaque cells against cellular oxidative stress by polarizing mitochondria not to release 
cytochrome c [54]. In this reason, autophagy of VSMCs of the fibrous cap in advanced ath-
erosclerotic lesion is important to plaque stabilization. Autophagic death in VSMCs results 
from excessively stimulated autophagy, and results in plaque destabilization [53]. Autophagic 
death in endothelial cells affects to maintain the structure of the thrombotic plaques. In view 
of stabilizing plaque on the rupture-prone lesion, induction of autophagic macrophages 
might be a promising strategic role in plaque which is not obstructive into lumen but prone 
to rupture [55]. Dysfunctional autophagy stimulates accumulation of damaged mitochondria, 
ROS over-expression, and ceroid in human plaque. Continuously and excessively stimulated 
autophagy can initiate autophagic VSMCs death resulting in plaque destabilization because 
Atherosclerosis - Yesterday, Today and Tomorrow102
collagen synthesis in reduced and also the fibrous plaque cap gets thinning. Of course, 
autophagic cell death is triggered in endothelial cells, which is detrimental role in the sustain-
ing structure of the atherosclerotic plaque. It is an acute clinical event promoting thrombosis 
on the atherosclerotic lesion.
Lipid modification such as LDL oxidation brings about a range of modifications with various 
physiological and biochemical properties [8]. Modified lipids in macrophage cells are able to 
induce lysosomal dysfunction which can result in the accumulation of intra-lysosomal cho-
lesteryl esters [56]. A number studies have shown that uptake of modified lipids induces a 
lysosomal lipid storage disease-like condition [5]. Accumulated lipids in lysosomes cause lyso-
somal dysfunction and affects the intracellular transport machinery. When macrophages are 
exposed to oxLDL and cholesterol, so-called atherogenic or modified lipids, lysosomal dysfunc-
tion occurs [16]. The oxLDL-derived cholesteryl esters form cholesterol crystal when oxLDL-
derived cholesteryl esters are inefficiently hydrolyzed and transported in lysosomes [57]. 
Through CD36-dependent mechanisms, oxLDL is moved to macrophage lysosomes; choles-
terol crystals accumulate in the lysosomes. Cholesterol crystals beyond the dealing range ini-
tiate lysosomal damage and result in leaking lysosomes [57]. As an example, phagocytosis of 
apoptotic cells (efferocytosis) is detected in plaque progression and is regarded as a critical 
feature of increasing plaque complexity [5]. PRPs, cell surface receptors and also scavenger 
receptors, recognize modified lipids (oxLDL) and pathogens. Plasma levels of soluble CD36, 
one of scavenger receptors, are higher in the context of risk factors for the development of 
atherosclerosis such as diabetes [58]. The altered “eat-me” signals can also affect efferocytosis 
and the targets of apoptotic cells. For example, mice lacking complement factor C1q exhib-
ited efferocytosis dysfunction and atherosclerotic plaque burden [59]. In human atheroscle-
rotic plaques, efferocytosis is impaired and also shaded phagocytic receptors, which impedes 
phagocytic capacity of macrophages and involves activation of the inflammatory response 
[60]. The LDLR-related protein 1 (LRP1) is one of the important receptors interacting with 
C1q for opsonizing.
Prolonged oxidative damage induces protein misfolding and the accumulation of dysfunc-
tional proteins to be degraded [61]. Large protein aggregates are ubiquitinated, and the 
poly-ubiquitinated protein aggregates are shuttled to the autophagosome. This is generally 
performed via chaperone proteins such as p62/SQSTM1 [11]. The reason for inflammasome 
activation in the plaque is not currently unclear, but two mechanisms have been suggested. 
One is that inefficient mitophagy clearing of damaged mitochondria results in increasing 
reactive oxygen species (ROS), which induces inflammasome activation. However, the level 
of protein oxidation and superoxides are augmented in autophagy-deficient macrophages 
and atherosclerotic plaques [12]. The other mechanism is that overloaded oxLDLs and choles-
terol crystals destabilize the lysosomal membrane, resulting in inflammasome activation by 
producing IL-1β [7]. In the atherosclerotic context, it has been shown that aggregated proteins 
activate inflammasomes and aggravate atherosclerosis in autophagy-deficient systems [12].
Atherosclerosis progression presents the features of impaired autophagy. Autophagy is sequen-
tial events called as autophagic flux (autophagosome formation, cargo sequestration, and auto-
lysosomal fusion), and unfortunately, hard to assess the flux in vivo. When p62/SQSTM1, a 
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chaperone shuttling protein aggregates from cytosol to autophagosomes, is combined to pro-
tein aggregates and degraded, increased level of p62/SQSTM1 indicate defective in autopha-
gic flux autophagy [62]. Correspondingly, deficient autophagy of macrophage can facilitate 
atherosclerotic plaque progression. Atg5 knock-out mice with ApoE-null background showed 
that western diet for 2 months increased the level of p62/SQSTM1 in the vessel with similar 
level of control mice whereas atherosclerotic lesion was bigger than control both in aortic root 
and whole aorta [62]. Using animals with experimental atherosclerosis, ApoE-null mice, recent 
study proposed that plaque formation expands when macrophagic autophagy is completely 
disrupted and not partially disrupted. Partially disrupted autophagic condition induces rather 
macrophagy inflammation and excess IL-1beta, because cholesterol crystal of atherosclerotic 
plaques is potent stimuli to activate inflammasome [62].
Cholesterol efflux is induced to balance the level of macrophage storing lipid by transfer-
ring increased cholesterol from peripheral tissues to the liver. The primary cholesterol efflux 
mechanism has been thought that cholesterols are hydrolyzed cholesteryl esters cytosolic 
hydrolases; free cholesterols are moved to the plasma membrane; finally free cholesterols 
are delivered to the periphery by ATP-binding cassette transporters (ABCA1 or ABCG1) 
[63]. Autophagic malfunction of macrophages abrogates this cholesterol efflux when mac-
rophages are faced to hinder autophage by chemically (chloroquine) or genetically (Atg5-
deficiency). Furthermore, inhibitors of lysosomal acid lipase also diminish cholesterol efflux. 
These showed that cholesterol hydrolysis as well as autophagic delivery is a critical step in 
atherosclerotic plaque progression and regression. Although lipid-laden macrophages induce 
lipophagy and also trigger a counter regulatory mechanism are unclear, it is clear that lipo-
phagy-mediated efflux plays an important role in cholesterol transport in vivo [7]. Therefore, 
efficient cholesterol metabolism and efflux considered athero-protective mechanisms against 
accumulated lipid-laden atherogenic condition [64].
4. Cognitive impairment after atherosclerosis
Aging is a major risk factor for neurodegenerative disease associated with atherosclerosis 
[65]. Previous studies have demonstrated a strong association between aging and vascular 
diseases. Recent clinical investigations have focused on the relationship between levels of cir-
culating adhesion factors in peripheral blood and cerebrovascular diseases [66]. Platelets and 
leukocytes play a major role in atherothrombosis, aggregates of which result in the formation 
of atherosclerotic plaques [67]. Although other factors associated with vascular disease can 
influence the cognitive state, few studies have utilized flow cytometry to investigate platelet 
and leukocyte markers in older adults with cognitive decline. Research has demonstrated a 
correlation between circulating adhesion molecules in patients with atherosclerosis and ath-
erosclerosis factors such as intima-media thickness (IMT) and the number of plaques, which 
may assist in determining the presence and/or extent of cognitive decline [68]. To determine 
the potential usefulness of this correlation for determining diagnoses/prognoses, blood factor 
analysis is required. Based on the pathophysiological mechanism underlying dementia, most 
relevant studies have aimed to identify molecular markers based on drug responses [69]. As 
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such, little is known regarding the potential role of circulating adhesion molecules in patients 
with vascular diseases during the early and later stages of cognitive dysfunction.
Many definitions have been proposed for the transition point when healthy aging with a 
slight cognitive decline progresses to dementia [70]. Mild cognitive impairment (MCI), which 
was first proposed by a group of investigators from the Mayo Clinic in the late 1990s [70], was 
defined to be based on a memory problem. This section provides our results about assessing 
the relationship between changes in blood factors and ultrasound findings in patients with 
MCI and dementia who were also exhibiting signs of atherosclerosis.
4.1. Atherosclerosis and dementia
Carotid atherosclerosis severity is assessed by considering the plaque number, proportions, 
and location as well as the presence of carotid stenosis that is caused by plaques. Additionally, 
the severity of carotid stenosis is determined according to the blood flow velocities, residual 
rumen diameter, and carotid artery flow velocities ratio to internal carotid artery versus the 
common carotid artery [71]. For AD, it is generally accepted that vascular risk factors have an 
epidemiological effect on dementia [72]. It has been reported that a narrowed carotid lumen 
is a risk factor for cognitive impairment in steno-occlusive carotid artery disease patients 
[72]. Revascularization procedures may have some benefit in the alleviation of dementia, but 
not for all of these patients [72]. In cases of mild AD with severe asymptomatic intra-carotid 
artery (ICA) stenosis, cognitive decline progressed even though they have not experienced 
cerebral ischemia [72]. One possible explanation of this relationship is that insufficient cere-
brovascular flow causes cerebral atrophy. Another one is vascular factors that are promoting 
the degenerative changes of AD [72].
The available studies have identified factors associated with aging and vascular dysfunction 
that exhibit a cross-sectional relationship with mental status based on the Mini-Mental State 
Examination (MMSE) score. Recent studies have reported that carotid artery atherosclerosis 
is associated with a subsequent risk of new or recurrent cerebrovascular diseases, such as 
stroke, post-stroke vascular dementia, and MCI [66, 73, 74]. Furthermore, chronic hypoper-
fusion caused by carotid stenosis has been reported to play a role in cognitive decline [75]. 
Dementia represents a major public health concern [68], as accumulating evidence has dem-
onstrated that the incidence and prevalence of dementia increases rapidly with advancing 
age. Although it has been difficult to investigate changes in the incidence and prevalence of 
dementia due to variations in diagnostic criteria and methods, a recent epidemiological study 
indicated that the dementia prevalence and incidence have decreased in some countries. 
Moreover, the number of patients with dementia has remained stable in the aging population 
of these countries [76]. Some evidence has suggested that vascular risk factors are associated 
with the onset and progression of AD [77]. There are increasing concerns that microvascular 
disease and tau deposition are found concomitantly and it is thought that treating vascu-
lar risk factors is as important as preventing cognitive decline [66]. Although the association 
between anterior cerebral artery (ACA) plaques and dementia has not been fully determined 
for the number and the location of plaques, it can be used as a better indicator of disease pro-
gression and severity.
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In addition, increased cerebrovascular risk has been associated with more severe dementia 
and a higher MCI incidence [78]. Considering the role of vascular blood factors in patients 
with MCI, such factors may also influence the progression of cognitive decline [79]. However, 
there are currently no markers for the prediction of prognosis or the risk of conversion from 
MCI to dementia. Therefore, it is necessary to develop noninvasive diagnostic methods for 
the assessment of vascular status [80]. This aspect is discussed in more detail in the next sub-
section with my results.
4.2. Neurosonological findings of atherosclerosis and dementia
In our recent study, we demonstrated that alterations in IMT and plaque number are associ-
ated with an increased risk of cognitive decline as well as a risk of dementia. Our results sug-
gest that ultrasound findings may aid in identifying older individuals at increased risk for the 
progression of cognitive decline when morphological impairment of cerebrovascular struc-
tures has been identified. Moreover, our findings suggest that the presence of atherosclerotic 
changes and changes in blood factors such as p-selectin glycoprotein ligand (PSGL, CD162), 
platelet-leukocyte aggregation (PLA), and platelet-monocyte aggregation (PMA) can be used 
to predict MCI and dementia.
Our study showed that levels of p-selectin in circulating platelets, PSGL, and circulating 
platelet-monocyte aggregates were significantly increased in patients with MCI relative to 
controls. The changes in circulating blood factors have been reported to relate with vascular 
diseases such as ischemic stroke or atherosclerosis [81]. Based on this association, several 
noninvasive measures for evaluating subclinical atherosclerosis have received intense atten-
tion in clinical and research settings for the predictive diagnosis of cerebrovascular diseases. 
Researchers have suggested a relationship between atherosclerotic severity and circulating 
adhesion blood factors and atherosclerotic severity and cognitive decline in the above-men-
tioned reports. With one step further linked between them, our findings provide insight into 
the use of blood factor analysis (using FACS) as well as ultrasonographic evaluation of ves-
sel status in both clinical and research settings. Changes in platelet activation and monocyte 
distribution are observed in the early stages of atherosclerosis. Such changes are strongly 
associated with stroke onset, as demonstrated by various studies [82]. The monocyte recep-
tor CD14 and leukocyte antigen CD45 are best known for their crucial role in immunity. In 
addition, CD14 and CD16 are well-known biomarkers for atherosclerotic disease progression 
[67]. Research has also suggested that PSGL is a pro-atherogenic marker of vascular disease 
progression [67].
The present study shows that increased IMT was more frequently observed in patients with 
MCI, whereas increased numbers of carotid plaques were more frequently observed in 
patients with dementia. The patients with MCI in our study comprise 32% of all patients with 
atherosclerosis, and all patients of the MCI group in the present study had been diagnosed 
with carotid vascular stenosis or atherosclerosis. These findings suppose that vessel dam-
age is followed by MCI. A lot of findings in previous studies suggest that greater degrees of 
carotid atherosclerosis are associated with the progression from MCI to dementia [66, 68, 78]. 
A recent study reported that up to 50% of patients develop vascular stenosis, and that ACA 
Atherosclerosis - Yesterday, Today and Tomorrow106
plaques are associated with dementia even after controlling for vascular risk factors [66]. 
Other researchers have suggested that atherosclerosis plays a role in cognitive impairment, 
particularly in older adults [83]. Such research has further demonstrated a converging rela-
tionship between degenerative vascular dysfunction and cognitive dysfunction. In our study, 
most patients with MCI exhibit atherosclerotic vessel abnormalities, such as increased IMT 
and plaque numbers, increasing the risk for progression to dementia. An estimated 15–42% 
of people over the age of 65 years exhibit some form of MCI, and approximately 5–15% of 
patients with MCI go on to develop dementia [70]. Recent evidence has revealed that vessel 
dysfunction contributes to AD as well as vascular dementia [84]. In this previous study, the 
authors reported an IMT cutoff value of 0.805 for the prediction of MCI development (base-
line: 0.825 mm) [84]. Diagnosis of dementia in such patients is required in order to ensure the 
appropriate therapeutic guidelines and treatments are utilized [76].
Our results indicated that intima thickness and plaque number are associated with higher lev-
els of p-selectin, supporting the evidence that platelets are engaged in the formation of PLAs 
[85]. In the dementia group of the present study, which included individuals with demen-
tia, plaque numbers corresponded strongly with levels of PSGL-positive platelets. Control of 
plaque numbers with appropriate therapy such as statin treatment may thus delay or prevent 
the progression of cognitive decline to dementia. Our findings also indicated that carotid ath-
erosclerosis correlates with MCI as well as increased numbers of PSGL-expressing platelets. 
Analysis of blood factors using ultrasonography may aid clinicians in determining the most 
appropriate treatment strategy for patients with cognitive decline with vessel disease. Our 
simple assessment of vascular risk factors does not seem to be a fully satisfactory approach 
for adequately counteracting the risk of developing dementia, when compared to other large-
scale studies [86]. Nevertheless, we suggest that analysis of circulating adhesion factors may 
aid in predicting the risk of progressive cognitive impairment. Additionally, aggressive treat-
ments for vascular disease should be considered for individuals with a predisposition toward 
dementia. Despite these limitations, our findings provide a basis for a future study regarding 
biomarkers of both cerebrovascular disease and cognitive dysfunction.
In conclusion, our findings demonstrate that circulating adhesion molecule levels and inter-
action between factors present significant differences in patient with MCI or dementia. 
Alterations in IMT and plaque number are associated with an increased risk of cognitive 
decline as well as conversion from MCI to dementia. These results suggest that ultrasound 
findings may aid in identifying older individuals at increased risk for the progression of cog-
nitive decline when there is cerebrovascular damage. Moreover, our findings suggest that the 
presence of atherosclerotic changes and changes in blood factors such as p-selectin, PSGL, 
PLA, and PMA can be used to predict the progression of MCI and dementia.
4.3. Prevalence and incidence of MCI and dementia in atherosclerosis
The World Alzheimer Report 2015 announced the estimate that 46.8 million people world-
wide have dementia, and this number is expected to increase to 74.7 million by 2030 and 131.5 
million by 2050 [76]. Accordingly, due to concerns about the increasing incidence of dementia, 
dementia is predicted to be ‘epidemic’ and a consequent economic burden. The G8 dementia 
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summit in 2013 and the WHO Ministerial Conference in 2015 decided to engage in a global 
action against dementia. The Atherosclerosis Risk in Communities (ARIC) study performed 
in 1987–1989 enrolled 15,792 individuals: they were a bi-racial group, with an age range from 
45 to 64 years, from 4 US communities. Cognitive assessments were performed in the second 
ARIC examination in 1990–1992 [74]. A comprehensive dementia study, Atherosclerosis Risk 
in Communities Neurocognitive Study (ARIC-NCS), was used as the fifth ARIC examination 
in 2011–2013. They evaluated what happens to participants with extensive cardiovascular 
disease and cognitive dysfunction after a long history of ARIC and for the participants who 
died. This is a longitudinal cohort depicting the association of cognitive function, cardiovas-
cular condition, cerebrovascular condition, and mortality. In ARIC-NCS, they reported that 
the overall prevalence of dementia in living ARIC participants is similar to the estimate of the 
World Alzheimer Report 2015. Although the prevalence of MCI in ARIC-NCS and the preva-
lence of MCI have been reporting to be at a similar level, there is a variation in MCI prevalence 
because of different MCI definitions [74]. Therefore, longitudinal studies of incident dementia 
in this cohort are required for validation of the MCI definition.
From some studies, it is obvious that the prevalence of dementia is related to stroke, heart 
disease, hypertension, and diabetes. These results are limited because many medications used 
to treat cardiovascular disease and other vascular diseases have been observed to have an 
effect on dementia prevalence and incidence. This is why no single factor has been identified 
to fully explain the changes in dementia prevalence and incidence. However, it is important to 
identify multiple risk factors and protective factors throughout a personal whole life-course 
relating to physical, mental, and cognitive health. In particular, atherosclerotic and vascular 
risk factors need to be well-controlled for reducing the risk of dementia in later life.
5. Prospects of therapy
For developing new therapeutic strategies for atherosclerosis, it is important to understand 
the cause of the disease pathogenesis and its progression [33]. A number of studies have 
shown that cell deaths produce different patterns depending on the stage of the plaque and 
types of cells involved in cell death. In summary, atherosclerosis is an inflammation-related 
arterial intima disease. A number of pharmacologic approaches have developed the way to 
stabilize rupture-prone atherosclerotic lesion by applying macrophage autophagic death. For 
therapeutic approach in atherosclerosis, it should be implicated for plaque stability and selec-
tive depletion of macrophages by modulating sterols. This section will introduce them.
5.1. Harnessing macrophagic autophagy as a therapy for atherosclerosis
One such pathway regulating the initiating autophagy involves mammalian target of rapamy-
cin (mTOR). Blocking mTOR using rapamycin has an effect on cell proliferation both in vitro 
and in vivo [87]. Inhibition of mTOR leads to autophagic cell death through some ATG protein 
pathways [88]. ATG13 is rapidly dephosphorylated when the mTOR pathway is inhibited. 
By stimulating affinity to ATG1, the ATG1-ATG13 complex is involved in autophagosome 
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formation. When the rapamycin derivative everolimus is delivered from a stent in athero-
sclerotic plaques, in the lesion site of cholesterol-fed rabbits, autophagic macrophage death 
occurred due to macrophage reduction. In contrast, the amounts of VSMCs were sustained 
without change [89]. An mTOR-mediated pathway induces dephosphorylation of p70 S6 
kinase, which is responsible for selective induction of macrophage death. On the other hand, 
the protein synthesis inhibitor cycloheximide induced selective macrophage death in plaques 
of cholesterol-fed rabbits. In this case, apoptosis occurred not only via autophagy, because 
plaque macrophages might be highly metabolic active and vulnerable to protein synthesis 
inhibitors relative to SMCs [90].
As another therapeutic case of rapamycin, inhibited translation of VSMCs leads to upregula-
tion of smooth muscle B-actin, calponin, and myosin heavy chain, which modulates VSMCs 
to be differentiated, quiescent, and have a contractile phenotype. As a result, VSMCs undergo 
cell death. It has been suggested that restricted protein translation might selectively induce 
macrophage cell death rather than cell death protein expression. mTOR gene silencing is 
another therapeutic approach. Transfection of mTOR-specific small interfering RNA selec-
tively induces macrophage cell death [89]. The recent evidence shows that the transcription 
factor TFEB works as a transcriptional activator for a network of autophagy and lysosomal 
genes [91]. The studies show that macrophage specific gene activator of TFEB has the ability 
of lysosomal biogenesis, recovering lysosomal dysfunction via atherogenic lipids. It allows 
some functions such as increasing cholesterol efflux, inhibiting inflammation activation, 
and clearing abnormal protein aggregate [16]. This study provides the possibility that over-
expressed TFEB in macrophages alleviates atherosclerosis [16].
Lipid reduction is the one of the well-known ways to eradicate macrophages from atheroscle-
rotic plaques [36]. One of recent studies using a rabbit atherosclerosis model suggested that 
the lower levels of lipid led not to macrophage apoptosis but instead monocyte recruiting 
impairment because of a decrease in macrophage replication. Statins are generally used in 
myocardial infarction patients. In SMCs treated with the autophagy inducer 7-ketocholes-
terol, fluvastatin failed to activate caspases. It has been suggested there is a possibility that 
activation of autophagy interferes with the statin-induced apoptotic pathway [36]. Another 
suggestion that has been proposed is that defective mitochondria are engulfed by autopha-
gosomes, which limits the relocation of pro-apoptotic molecules from mitochondria into the 
cytosol or nucleus [36].
5.2. Treating atherosclerosis as a therapy for cognitive impairment
Currently, statin drugs are major therapeutics to prevent acute coronary events. Statins inhibit 
cholesterol biosynthesis, reduce LDL receptors (LDLRs), and consequently trigger a reduction 
in blood cholesterol levels [92]. Statins work at multiple stages in atherosclerotic plaque for-
mation. Among these stages, statins have effects at earlier atherosclerosis development stages 
because they hinder cholesterol accumulation, monocyte infiltration, and inflammation in 
arteries [92]. Carotid atherosclerosis is measured by two distinct characteristics: carotid intima-
media thickness (cIMT) and carotid plaque burden quantified by plaque presence or local-
ization. A recent study suggests that plaque burden may act as a predictor of cardiovascular 
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disease other than cIMT, although cIMT has been better represented in preventative measures 
[68]. It has been suggested that plaque numbers and cIMT may be involved in cognitive impair-
ment and dementia [66]. These studies report early intervention of atherosclerosis to prevent 
cognitive impairment [72]. It is obvious that carotid atherosclerosis can be a potential target for 
early intervention and risk management for those at risk for cognitive decline. A recent study 
was performed under the hypothesis that cognitive performance in the dominantly affected 
domain would be related to carotid plaque burden and cIMT, and cognitive decline would be 
shown differently in the racial and ethnical diverse Northern Manhattan Study (NOMAS) [93]. 
They indicated that elderly individuals with a larger cIMT have a higher future risk of progres-
sion to MCI or dementia. It is required to monitor patients for earlier detection of cognitive dys-
function [93]. Additionally, they identified a cutoff value for predicting cognitive impairment 
progression (0.825 mm of cIMT), which corresponds to the cutoff values for predicting stroke 
and CVD in the previous report [93].
Considering the role of vascular blood factors in patients with MCI, some blood factors sug-
gested in our previous study may also influence the progression of cognitive decline [94]. 
However, there are currently no markers for prognostication or the risk of conversion from 
MCI to dementia. Therefore, it is necessary to develop noninvasive diagnostic methods for the 
assessment of vascular status [80]. This aspect is discussed further in the next section along 
with my results. Our results may provide a route for determining the most appropriate treat-
ment strategy for patients with MCI or multiple diagnoses.
According to recent research, trends of dementia prevalence and incidence have been reported, 
which are based on healthcare and insurance databases, clinical records, and meta-analy-
sis. These studies have not currently provided how to control the recent trends of cognitive 
function about diagnosis, clinical details, or public awareness for it. Nonetheless, research-
ers and clinicians are agreeing that long-term determinants are needed for both healthy and 
unhealthy aging in the most of society. Furthermore, it goes on the efforts to reduce risk of 
dementia by maintaining health with age.
6. Conclusions
Clinically and pathologically, atherosclerosis is an important disease in a worldwide aging 
society. It has been shown that innate immune factors and adaptive immune factors are 
associated with the atherosclerotic process since inflammatory mechanisms are identified as 
major causes in patients. A number of studies have identified several potential targets for 
therapy. Unfortunately, however, inflammation is an independent risk factor for atheroscle-
rosis progression in humans. Researchers have tried to evaluate the mechanism of immune-
related therapies in atherosclerotic cardiovascular disease. Along with inflammation-related 
mechanisms, autophagy in atherosclerosis is also responsible for the foam cell formation and 
insoluble oxLDL uptake and clearance in human atherosclerotic lesions. Autophagic macro-
phages produce pro-inflammatory cytokines such as TNF-beta and interleukin-6, and these 
cytokines are not immunologically silenced during the autophagic process. Lipid droplets 
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are spilled from lipid-overloaded macrophages in the plaques. Based on previous research, 
future studies are focusing on therapeutic advantages of autophagic microphages in unstable 
atherosclerotic plaques.
Despite efforts to develop strong therapeutic targets, it is not feasible to establish respec-
tive contributors to degeneration and vascular disease onset and progression in each patient. 
Today, in our aging society, dementia has becoming an important issue in the public heath, 
economics, and social aspects, and also in political fields. With careful converging and treat-
ing on vascular risk factors containing atherosclerosis, it would get available therapeutic strat-
egies for prognosis and diagnosis in patients with progressive dementia.
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